Abstract:Introduction: Recurrence after liver transplantation (LT) for hepatocellular carcinoma (HCC) is a major cause of mortality. Lenvatinib and sorafenib are the first line choice in untreated advanced hepatocellular carcinoma. However, their efficacy in patients with LT is still unknown. We analyzed our 5-year experience with LT for HBV related HCC to identify predictors of recurrence and potential beneficiaries from targeted therapy of Lenvatinib or sorafenib. Materials and Methods: A novel clinicopathologic risk score predicting post-transplant HCC recurrence was developed from a multivariate competing-risk Cox regression analysis of 165 LT recipients with HCC between 2014 and 2019 in Huashan hospitals affiliated to Fudan university. The inclusion criteria: 1) histologically proven to be HCC; 2) without extrahepatic metastasis. The exclusion criteria: 1) concurrent malignancy; 2) died within 1 month; 3) other malignancies; 4) without a complete clinicopathologic records. The association of the risk score with recurrence and response to targeted therapy was assessed. Results and Discussion: The mean follow-up period was 20 months, ranging from 1 to 60 months. A total of 165 cases were included. Overall patient and recurrence-free survivals were 92%, 84%, 77% and 86%, 74%, and 67% at 1-, 2-, and 3-years, respectively. 35 patients experienced tumor recurrence and the median disease-free survival (DFS) was 14 months. Multivariate predictors of recurrence included preoperative AFP (>200ng/ml hazard ratio [HR] 2.76), preoperative GGT(> 96U/L [HR] 2.76) and exceeding Hangzhou criteria (HR 1.98). Thus, AFP_GGT_Hangzhou (AGH) score was established based on the combined scores of AFP, GGT, and Hangzhou criteria. Patients meet at least two factors, defined as high risk, one as medium risk and none as low risk(Figure 1). AGH score, incorporating only known radiographic and laboratory parameters, had improved accuracy in predicting HCC recurrence (C statistic 0.74) compared with both Milan (C statistic 0.63) and UCSF (C statistic0.64) criteria alone. Furthermore, AGH score was the only independent risk factor affecting OS and DFS. AT last, only in the high risk group of HCC patients, can we found an improvement on DFS for taking adjuvant targeted treatment (sorafenib[P=0.043] or lenvatinib[P=0.027] vs. control group, Figure 2). Conclusion: AGH score may have the potential to serve as a predictor of recurrence and beneficiaries from targeted drug therapy in HBV related HCC patients following LT. This work was supported by China National Natural Science Foundation (81672365).

The 4th Asia-Pacific Primary Liver Cancer Expert Meeting

[Ten-Year Retrospect of ALPPS in the Treatment of Hepatocellular Carcinoma:An Eternal Concept with Cautious Technologic Choice].

Clonal Origin of Hepatocellular Carcinoma and Recurrence after Liver Transplantation

Alpha-Fetoprotein and Novel Tumor Biomarkers as Predictors of Hepatocellular Carcinoma Recurrence after Surgery: A Brilliant Star Raises Again

Metastasis and Recurrence after Surgical Resection of Hepatocellular Carcinoma: Recent Progress in Clinical and Related Basic Aspects

The 5th Asia-Pacific Primary Liver Cancer Expert Meeting (APPLE 2014): A Bridge to a Consensus on HCC Management, Taipei, Taiwan, July 11-13, 2014

α-Fetoprotein, α-Fetoprotein-L3, and Des-γ-Carboxy Prothrombin Stratify Hepatocellular Carcinoma Treatment Response and Progression Risk

Research hotspots and updates of diagnosis and treatment of hepatocellular carcinoma from 2017 annual meeting of the American Society of Clinical Oncology

The Value of Serum α-Fetoprotein in Predicting Tumor Recurrence After Liver Transplantation for Hepatocellular Carcinoma

AFP, AFP-L3, DCP, and GP73 as markers for monitoring treatment response and recurrence and as surrogate markers of clinicopathological variables of HCC

Current approaches to the treatment of early hepatocellular carcinoma.

Incorporating Tumor Biology to Predict Hepatocellular Carcinoma Recurrence in Patients Undergoing Living Donor Liver Transplantation Using Expanded Selection Criteria

EpCAM-positive circulating tumor cells and serum AFP levels predict outcome after curative resection of hepatocellular carcinoma

176P Effect of Adjuvant Lenvatinib (LEN) on Tumour Recurrence in Patients with Hepatocellular Carcinoma (HCC) and High Residual Alpha-Fetoprotein (AFP) Following Resection or Ablation: A Single-Center, Retrospective Study

[Prognostic factors and outcome in patients with intrahepatic recurrence after hepatectomy for hepatocellular carcinoma]

Combined Detection Of Circulating Tumor Cells, Alpha-Fetoprotein Heterogene-3 And Alpha-Fetoprotein In The Early Diagnosis Of Hcc For The Prediction Of Efficacy, Prognosis, Recurrence After Microwave Ablation

AGH SCORE PREDICTS RECURRENCE AND RESPONSE TO ADJUVANT-TARGETED THERAPY IN HBV RELATED HCC AFTER LIVER TRANSPLANTATION

Radiofrequency ablation for the treatment of recurrent hepatocellular carcinoma：analysis of the therapeutic results and prognostic factors

Impact of treatment modalities on patients with recurrent hepatocellular carcinoma after liver transplantation: Preliminary experience

The Predictive Value of the Modified AFP Model for Liver Transplantation Outcomes in Multinodular Hepatocellular Carcinoma Patients

Recurrence after Resection of Alpha-Fetoprotein-Positive Hepatocellular-Carcinoma